[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338567-105":59,"doc-detail-338567-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-real-world-disproportionality-analysis-of-the-us-food-and-drug-administration-fda-adverse-event-reporting-system-faers-events-for-durvalumab","A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab","","Retrospective analysis evaluated adverse events (AEs) associated with durvalumab using data from the US Food and Drug Administration adverse event reporting system (FAERS) to clarify its toxicological profile. The study covered 2004–2024 and applied four disproportionality algorithms—ROR, PRR, BCPNN, and MGPS—supported by SAS 9.4. Results identified 17,629,340 nonduplicated patients and 19,709 AE cases, with six preferred terms significantly disproportionate across all methods. Common AEs included death, radiation pneumonitis, pneumonitis, and lung disorders, with additional reports such as central nervous system metastases and drug-induced liver injury.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-real-world-disproportionality-analysis-of-the-us-food-and-drug-administration-fda-adverse-event-reporting-system-faers-events-for-durvalumab/338567/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-real-world-disproportionality-analysis-of-the-us-food-and-drug-administration-fda-adverse-event-reporting-system-faers-events-for-durvalumab/338567.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which data source and time period were used to study durvalumab-related adverse events?","Question",{"text":113,"@type":114},"The analysis used the US FDA adverse event reporting system (FAERS) covering the period 2004 to 2024.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were durvalumab-associated AEs quantified in the study?",{"text":118,"@type":114},"Four algorithms were used: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and mu-item gamma Poisson shrinker (MGPS), with SAS 9.4 for statistical analysis.",{"name":120,"@type":111,"acceptedAnswer":121},"What adverse events were reported as commonly occurring in the target population?",{"text":122,"@type":114},"Commonly reported AEs included death, radiation pneumonitis, pneumonitis, and lung disorders.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338567,1790188817,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Zou etal. BMC Pharmacology and Toxicology (2024) 25:97  \n[https://doi.org/10.1186/s40360-024-00821-y](https://doi.org/10.1186/s40360-024-00821-y)  \nBMC Pharmacology and Toxicology  \nRESEARCH Open Access  \nA real-world disproportionality analysis of the  US Food and Drug Administration (FDA) adverse event reporting system (FAERS)  \nevents for Durvalumab  \nTing Zou 1†, Zhuoyang Li2†, Tianhong Wang3, Shuang Deng4, Siman Wang3 andYusi Hua3*  \nAbstract  \nBackground In the past few years, an increasing number of research studies have documented the utilization of durval umab in the field of immunotherapy for cancerous tumors. However, there remains insufficient documentation regarding its associated adverse event (AEs) . In order to enhance our comprehension of its toxicological profile, this investigation retrospectively examined the AEs linked to durval umab using data from the US Food and Drug Administration adverse event reporting system (FAERS) .  \nMethods Using data from FAERS for the period 2004 to 2024, the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and mu-item gamma Poisson shrinker (MGPS) four algorithms were used to quantify durval umab related AEs. SAS 9.4 was used for statistical analysis.  \nResults We collected nonduplicated reported 17,629,340 patients from the FAERS database and 19,709 AEs cases in the target population with durval umab as the primary drug of suspicion. There were 6 significantly disproportionate preferred terms (PTs) that fit all four algorithms simultaneously. The AEs commonly reported include death, radiation pneumonitis, pneumonitis, and lung disorders. Furthermore, durval umab has been associated with additional AEs, such as metastases to the central nervous system and drug-induced liver injury.  \nConclusions The study revealed that durval umab immunotherapy is associated with AEs including death, radiation pneumonitis, pneumonitis, metastases to the central nervous system, lung disorder and drug-induced liver injury. In clinical practice, it is crucial to be vigilant and prevent the occurrence of these AEs.  \nKeywords Durval umab, FAERS, PD-L1, Adverse events  \n†Ting Zou and Zhuoyang Li contributed equally to this work and should be considered as co-first authors.  \n*Correspondence:  \nYusi Hua  \n[yusihua@wchscu.cn](yusihua@wchscu.cn)  \n1Department of Anesthesiology, West China Hospital, Sichuan University/ West China School of Nursing, Sichuan University, Chengdu,  \nSichuan Province 610041, China  \n2School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China  \n3Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China  \n4The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, Sichuan Province 610041, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nZou et al. BMC Pharmacology and Toxicology (2024) 25:97  \nIntroduction ","cbCaiclUInlKlVIo","https://ap.wps.com/l/cbCaiclUInlKlVIo","pdf",982645,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Immunotherapy for malignant tumors\n## PD-1/PD-L1 and CTLA-4 pathways\n## Available immunotherapeutic agents including durvalumab","[{\"question\":\"Which data source and time period were used to study durvalumab-related adverse events?\",\"answer\":\"The analysis used the US FDA adverse event reporting system (FAERS) covering the period 2004 to 2024.\"},{\"question\":\"How were durvalumab-associated AEs quantified in the study?\",\"answer\":\"Four algorithms were used: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and mu-item gamma Poisson shrinker (MGPS), with SAS 9.4 for statistical analysis.\"},{\"question\":\"What adverse events were reported as commonly occurring in the target population?\",\"answer\":\"Commonly reported AEs included death, radiation pneumonitis, pneumonitis, and lung disorders.\"}]","A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab | PDF",1790024299,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6adda1e64b1ed432ebbc1a7700767b0.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bd4a1efbbf0674a5ed54658b367b68d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f51034025f1622d12fc3e0258cad713.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ac885e5ca413a199eda92c1e3f62f57.webp",980,1306]